Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research results from M. Theodoulou and co-authors update knowledge of breast cancer
June 25th, 2009
"This was an open-label, nonrandomized, multicenter, 2-stage phase I trial of safety and preliminary efficacy of nonpegylated liposomal doxorubicin (NLD) in combination with trastuzumab in advanced breast cancer, with emphasis on cardiac toxicity. Forty patients (median age, 48 years; range, 30-74 years) with HER2/neu 2+ or 3+ tumors (by immunohistochemistry) were recruited December 1999 to November 2002," scientists in the United States report. "Patients were eligible if they received <= 1 previous trastuzurnab regimen, <= 2 cytotoxic regimens for advanced breast cancer, and lifetime cumulative anthracycline doses <= 240 mg/m(2). The study regimen comprised...
Source: Women's Health Weekly (2009-06-25)
|
